Vismodegib
- PDF / 130,590 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 6 Downloads / 131 Views
1
S
Keratoacanthoma: 2 case reports Two patients developed keratoacanthomas (KA) during treatment with vismodegib [routes not stated; outcome not clearly stated] for locally advanced basal cell carcinomas (BCC). A 100-year-old woman had eyelid BCC, which began to grow and impinge on her visual field. She also had an ulcerated tumour that involved her lower eyelid. She was started on vismodegib 150 mg/day. Two weeks later, she developed a rapidly enlarging mass on her upper arm. A squamous cell carcinoma (SCC), KA type, was confirmed with a biopsy. She underwent excision of the KA and continued vismodegib. Her eyelid BCC continued to regress. A 53-year-old man had a recurrent BCC affecting his left medial periorbital area. He started receiving vismodegib 150 mg/day. After 7 weeks of treatment, he showed complete clinical regression. At this time, he was noted to develop a nodule affecting the medial and inferior aspect of his left eyebrow. A biopsy revealed a SCC or KA. The KA was excised. Author comment: "Herein, we report 2 cases of new KAs developing within 2 months of starting vismodegib therapy". Aasi S, et al. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: A report of 2 cases. JAMA Dermatology 803085914 149: 242-243, No. 2, Feb 2013 - USA
0114-9954/10/1448-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 20 Apr 2013 No. 1448
